1 / 6

PharmaCog WP5 / E-ADNI

This study focuses on enrolling and following up with patients in the PharmaCog clinical sites, aiming to classify MCI patients using biomarkers and assess cognitive and hippocampal changes. The study also includes peer-reviewed publications and a special issue in a journal.

valeriet
Download Presentation

PharmaCog WP5 / E-ADNI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PharmaCog WP5 / E-ADNI

  2. PharmaCog WP5 / E-ADNI Clinical sites Enrollment and follow-ups PATIENTS EXPECTED Maximum Minimum

  3. Peer-reviewedPublications

  4. Baseline CSF Aβ, Aβ/t-tau and Aβ/p-tau distributions to classify PharmaCog MCI patients

  5. Cognitive and hippocampal volume changes

  6. Peer-reviewedPublications Series of papers in preparation The IMI PharmaCog WP5/European ADNI study: status and progression of prodromal AD as revealed by a matrix of clinical, neuropsychological, and biological markers Special issue of peer-reviewed journal Introduction Cross-sectional papers Longitudinal papers 22 papers divided into

More Related